

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

In the name of Allah
the Most Gracious
the Most Merciful

seminar1

Apoptosis and cancer therapy

Presented by: Rostamy.A

Under supervision : Dr. Ahmadpour.

Paramedicine faculty

Qazvin university of medical science

contents

1)Intoduction (4-33)

- a)Morphological change.....(6-10)
- b)Biochemical change.....(11-16)
- c)extrinsic.....(20-24)
- d)intrinsic.....(24-34)

2)discussion.....(33-69)


- a)Oxidative strass.....
- b)p53.....
- c)bcl2.....
- d)trail/rhApo2L.....

3)Result.....(69-72)

4)Refrencess.....

Apoptosis and cancer therapy

number of article



Source:google scholar
Last updated:2017/4/14

Apoptosis

The term "apoptosis" is derived from the Greek words "*απο*" and "*πτωσιζ*" meaning "*dropping off*" and refers to the falling of leaves from trees in *autumn*.



Introduction

Morphological changes in apoptosis

Morphological alterations of apoptotic cell death that concern both the nucleus and the cytoplasm are



remarkably **similar** across cell types
and species

Introduction

Morphological hallmarks of apoptosis in the nucleus are



chromatin condensation and nuclear fragmentation,




which are accompanied by

- 1) **rounding up** of the cell,
- 2) reduction in cellular volume (**pyknosis**)
- 3) retraction of **pseudopodes**

Introduction

Chromatin condensation starts at the periphery of the



- 1) **nuclear** membrane,
- 2) forming a **crescent** or
- 3) ring-like structure


Introduction

The **chromatin** further
condenses



until it **breaks up** inside a cell
with an intact membrane, a
feature described as
karyorrhexis

he **plasma membrane** is



intact throughout the total
process

Introduction

At the **later stage of apoptosis** some of the morphological features include

- 1) membrane **blebbing**
- 2) **ultrastructural modification** of cytoplasmic organelle
- 3) and a **loss of membrane integrity**(1)

Biochemical changes in apoptosis

- 1) activation of **caspases**,
- 2) **DNA** and protein breakdown and
- 3) membrane changes and recognition by **phagocytic cells**

Early in apoptosis

here is expression of **phosphatidylserine (PS)** in the outer layers of the cell membrane

which has been "**flipped out**" from the **inner layers**. This allows early recognition of dead cells by **macrophages**,

resulting in phagocytosis **without** the release of **pro-inflammatory** cellular components

Introduction

Early in apoptosis

This is followed by a
characteristic

breakdown of DNA into



large 50 to 300
kilobase pieces

Later

there is

internucleosomal cleavage of DNA



into **oligonucleosomes** in multiples of

180 to 200 base pairs by

Endonucleases(2)

Introduction

Another specific feature of apoptosis is the activation of a **group of enzymes** belonging to



to the cysteine protease family named caspases.

The "c" of "caspase" refers to a **cysteine protease**, while the "aspase" refers to the enzyme's unique property to **cleave after aspartic acid residues**

Introduction

Activated caspases



- 1) cleave many vital cellular proteins
- 2) and break up the nuclear scaffold and cytoskeleton.
- 3) They also activate DNAase, which further degrade nuclear DNA(3)

Introduction

Mechanisms of apoptosis

Caspases are central to the mechanism of apoptosis as they are both the

initiators and **executioners**



There are three pathways by which

caspases can be activated

Introduction

The **two** commonly described

initiation pathways are the

1) **intrinsic** (or mitochondrial)

2) and **extrinsic** (or death receptor)

3) A third less well-known initiation pathway is the **intrinsic endoplasmic reticulum** pathway(4)



The **extrinsic** death receptor pathway

The extrinsic death receptor pathway

the **best** known death receptors is
the type



1 TNF receptor (**TNFR1**)
and a related protein called Fas
(**CD95**)

and their ligands are called
TNF and **Fas ligand (FasL)**
respectively

The **extrinsic** death receptor pathway

These **death receptors** have an




- 1) **intracellular death domain** that recruits adapter proteins such as TNF receptor-
- 2) **associated death domain** (TRADD) and
- 3) **Fas-associated death domain** (FADD), as well as cysteine proteases like caspase 8

The **extrinsic** death receptor pathway

the **whole ligand-receptor-adaptor protein complex** is known as

the death-inducing signalling complex (DISC)



DISC then initiates the assembly

and activation of **pro-caspase 8**

A microscopic image of a cell, likely a mitochondrion, showing internal structures like cristae. The image is in shades of blue and purple. A large yellow rectangular box is overlaid in the center, containing the title text.

The **intrinsic** mitochondrial pathway

The **intrinsic** mitochondrial pathway

Internal
stimuli such as

- 1) irreparable **genetic damage**
- 2) **hypoxia**,
- 3) extremely high concentrations of **cytosolic Ca^{2+}**
- 4) and **severe oxidative stress** are some triggers of the initiation of the intrinsic mitochondrial pathway

The **intrinsic** mitochondrial pathway

Regardless
of the
stimuli

this pathway is the result of

increased mitochondrial permeability
and the release

of pro-apoptotic molecules such as
cytochrome-c into the cytoplasm

The **intrinsic** mitochondrial pathway

This pathway is closely regulated by a group of proteins belonging to the **Bcl-2 family**, named after the **BCL2** gene originally observed at the

chromosomal breakpoint of the translocation of chromosome **18 to 14** in follicular **non-Hodgkin lymphoma**

The **intrinsic** mitochondrial pathway

There are **two** main groups of the **Bcl-2** proteins



1)namely the **pro-apoptotic** proteins (e.g. Bax, Bak, Bad, Bcl-XBs, id, Bik, Bim and Hrk)

2)and the **anti-apoptotic** proteins (e.g. Bcl-2, Bcl-X_L, Bcl-W, Bfl-1 and Mcl-1)

The **intrinsic** mitochondrial pathway

Other apoptotic factors that
are released from the mitochondrial
intermembrane space into the cytoplasm include

- 1) apoptosis inducing factor (**AIF**)
- 2) second mitochondria-derived activator of caspase (**Smac**)
- 3) direct IAP Binding protein with Low pI (**DIABLO**)
- 4) and Omi/high temperature requirement protein A (**HtrA2**)

The **intrinsic** mitochondrial pathway

Cytoplasmic release of

cytochrome c activates caspase 3 via the formation of

a complex known as **apoptosome** which is made up



1) **cytochrome c**

2) **Apaf-1**

3) **and caspase 9**

The **intrinsic** mitochondrial pathway

Smac/DIABLO or Omi/HtrA2

promotes caspase activation by



binding to inhibitor of apoptosis
proteins (**IAPs**)

which subsequently leads to disruption
in the interaction of IAPs with **caspase-
3 or -9**

The intrinsic endoplasmic reticulum pathway

It is believed to be
caspase 12-dependent
and mitochondria-independent



When the ER is injured by

cellular stresses like

1) hypoxia

2) free radicals or

3) glucose starvation(5)

Introduction

Apoptosis and carcinogenesis

Disrupted balance of
pro-apoptotic and
anti-apoptotic
proteins

The Bcl-2
family of
proteins

p53

(IAPs)

Reduced **capsase** activity

Impaired **death receptor**
signaling(6)



Cancer therapy via

The **extrinsic** death receptor pathway


Discussion

RhApo2L/TRAIL effectively
induces apoptosis *in vitro* in a broad
spectrum of cancer cell lines,
including

- 1)lung
- 2)colon
- 3)pancreas and
- 4)lymphoma

Discussion

RhApo2L/TRAIL also has demonstrated single-agent activity **in vivo** in preclinical tumor models based on

- 
- 1) **SCID**
 - 2) athymic nude mice bearing **CRC**
 - 3) **NSCLC**
 - 4) non-Hodgkin's lymphoma (**NHL**) xenografts.

Discussion

Preclinical Safety of rhApo2L/TRAIL

In the first of two studies,
cynomolgus monkeys were
administered
rhApo2L/TRAIL at doses of.

0,
0.1,
1.0,
or 10 mg/kg/d

For

7 days


Discussion

Preclinical Safety of rhApo2L/TRAIL

Neither detectable signs of liver toxicity nor changes in **liver enzyme activity** were observed

no evidence of toxicity to any other major organ system or tissue was detected.(6)

Activity of rhApo2L/TRAIL and rituximab



<http://www.bloodjournal.org/content/110/12/4037?ssu-checked=true>

LAST UPDATE:12/04/2017

- 1) Mice (n = 12 mice/group) were then treated with vehicle (black x),
- 2) 60 mg/kg rhApo2L/TRAIL (closed blue circle),
- 3) 4 mg/kg rituximab (open green triangle),
- 4) 10 mg/kg rituximab (open red square),
- 5) rhApo2L/TRAIL and 4 mg/kg rituximab (closed green triangle),
- 6) or rhApo2L/TRAIL and 10 mg/kg rituximab (closed red square).



Cancer therapy via



The **intrinsic** mitochondrial pathway

Discussion

Oxidative Stress

Oxidative stress is a biochemical condition that is characterized by the **imbalance** between

the presence of

relatively high levels of **toxic reactive species**

Discussion

Oxidative Stress


1) reactive oxygen species (**ROS**),

2) reactive nitrogen species (**RNS**),

3) and the **antioxidative** defense mechanisms. 1–3
ROS and RNS

are **organic** or **inorganic** molecules that have an odd number of **electrons**

Oxidative Stress



<http://www.in-corpore.ch/news/oxidative-stress-nutrition/>


Last update:2017/04/14

Discussion

Oxidative Stress

The **biological functions of oxidative stress**

and its
potential role in cancer
development and progression



have been **investigated** for
several decades.
Cancer itself induces
oxidative stress

Discussion

Oxidative Stress

actually
ROS levels have been found
to be significantly
higher and

GPX and **SOD** activities
significantly
lower in cancer patients than
controls(7)

Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis

L. Ouyang^{*2}, Z. Shi^{†‡2}, S. Zhao^{†2}, F.-T. Wang^{*†}, T.-T. Zhou[§], B. Liu^{*} and J.-K. Bao[†]

**State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China, †Key Laboratory of Bio-resources and Eco-environment, Ministry of Education, School of Life Sciences, Sichuan University, Chengdu, China, ‡School of Life Sciences, Guizhou Normal University, Guiyang, China, and §Shanghai Key Laboratory for Pharmaceutical Metabolite Research, School of Pharmacy, Second Military Medical University, Shanghai, China*

Received 10 March 2012; revision accepted 9 July 2012

Abstract

Programmed cell death (PCD), referring to apoptosis, autophagy and programmed necrosis, is proposed to be death of a cell in any pathological format, when mediated by an intracellular program. These three forms of PCD may jointly decide the fate of cells of malignant neoplasms; apoptosis and

Introduction: a brief overview of programmed cell death

Programmed cell death (PCD) may balance cell death with survival of normal cells; the equilibrium becomes disturbed and PCD plays key roles in ultimate decisions of cancer cell fate (1,2). Of note, apoptosis, autophagy and programmed necrosis are the three main forms of

Discussion

Oxidative Stress

It is well **established** that some **chemotherapeutic agents and radiation therapy**



generate ROS in patients during cancer therapy

Discussion

Oxidative Stress

Chemotherapy agents can be divided into several categories

1) **alkylating agents** (e.g., cyclophosphamide, ifosfamide)

2) **anthracycline antibiotics** which affect nucleic acids (e.g., doxorubicin, bleomycin)

3) **platinum compounds** (e.g., cisplatin)

Discussion

bcl2

BCL2 is known to

1)prevent programmed cell death

2)increase
metastatic potential

3)and promote resistance to
anticancer
therapy.

Discussion

bcl2

High expression of the
BCL2 proto-oncogene is
found in various solid
tumours

G3139 is an antisense
phosphorothioate
oligodeoxynucleotide




that suppresses
BCL2 expression



Author Manuscript

Clin Cancer Res. Author manuscript; available in PMC 2011 September 28.



Published in final edited form as:

Clin Cancer Res. 2009 February 15; 15(4): 1126–1132. doi:10.1158/1078-0432.CCR-08-0144.

Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

Min H. Kang^{1,2} and **C. Patrick Reynolds^{1,3,4}**


¹ Cancer Center and the Department of Cell Biology and Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas

² Department of Pharmacology, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas

³ Department of Internal Medicine, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas

⁴ Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas

bcl2



[Source: en.wikipedia.org/wiki/Bcl-2#/media/File:BCL-2_human.png](https://en.wikipedia.org/wiki/Bcl-2#/media/File:BCL-2_human.png)

Last updated:12/04/2017

Discussion

bcl2

BCL2 antisense therapy is well tolerated

The first results of a phase I dose-escalation clinical trial evaluating subcutaneous administration of G3139(8)

Discussion

p53

One of the most advanced gene therapy agents used in the treatment of human cancer is

the replication-incompetent adenovirus that delivers a *p53* expression cassette,
RPR/INGN201

Discussion

p53

Preclinical studies in human cell lines and animals with **head and neck cancers** have shown

that the *p53* gene contained in RPR/INGN201 is efficiently transcribed and translated into p53 protein

Discussion

p53


Treatment with
RPR/INGN201

inhibited cell growth in human
SCCHN
cell lines of diverse p53 status



and suppressed tumour
growth in **animal** xenografts of
human **SCCHN** through the
apoptotic pathway and other
effects, such as inhibition of
angiogenesis.(9)

p53



<https://pdbe101.rcsb.org/motm/31>
LAST UPDATED:12/04/2017

dy

p53



<http://www.dailymail.co.uk/health/article-3173307>

LAST UPDETED:12/04/2017

Control of apoptosis by p53

Jordan S Fridman^{1,3} and Scott W Lowe^{*,2}

¹*Incyte Corporation, Wilmington, DE 19880*

²*Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA*

The p53 tumor suppressor acts to integrate multiple stress signals into a series of diverse antiproliferative responses. One of the most important p53 functions is its ability to activate apoptosis, and disruption of this process can promote tumor progression and chemoresistance. p53 apparently promotes apoptosis through transcription-dependent and -independent mechanisms that act in concert to ensure that the cell death program proceeds

most commonly inactivated tumor suppressor gene in human cancer (Hussain and Harris, 1998; Beroud and Soussi, 2003).

Although most of the attention on p53 has focused on its role in cancer, chronic activation of this key biological pathway may be equally as deleterious as its inactivation. In fact, hyperactivation of p53 has been associated with a variety of degenerative diseases such as

Discussion


CASPASE FAMILY

caspase-8 is mutated in
different
types of cancers

Soung and colleagues⁹⁴ screened **gastric carcinomas** (162 cases),
breast carcinomas (93 caspase),
non—
small cell **lung cancers** (NSCLC) (185 cases),
and 88 **acute leukaemias** (88 cases)

for mutations within the caspase-8 gene
using single strand conformation
polymorphism (SSCP)

CASPASE FAMILY



https://en.wikipedia.org/wiki/Caspase_8#/media/File:Protein_CASP8_PDB_1f9e.png

LAST UPDATED:12/04/2017

Discussion

CASPASE FAMILY

They found that the incidence of caspase-8 mutation in gastric cancer is statistically higher than those of

NSCLC
breast cancer,
and
acute leukaemias.

Furthermore, all of the 13 mutations detected were in advanced gastric cancers but not in early gastric cancers

Discussion

CASPASE FAMILY

The
mutations consisted of

1)three missense,

2)one in-frame deletion,
and

3)five frameshift mutations in the coding sequences;

.....

4)two

mutations in the initiation codon;

.....

5)three mutations in the

introns; and one mutation in the 3V untranslated region

Discussion

CASPASE FAMILY

Pancreatic cancer is one of the leading causes of cancer related death in the world.

1)Smoking,

2)diabetes mellitus history,

3)alcohol drinking

are risk factors for pancreatic carcinogenesis

Discussion

CASPASE FAMILY

It has been shown that
pancreatic cancer cells
often present

1) non-functional **CD95/Fas**

2) and aberrant expression of **FasL**

and this mechanism may contribute to
the **malignant**
and often **rapid** course of the disease

Discussion

CASPASE FAMILY

caspase-3 was mutated in one case in

- 1) **stomach adenocarcinoma**
- 2) one case in **lung cancer**,
- 3) four cases in **colon** cancer,
- 4) one case in **hepatocellular carcinoma**,
- 5) and one case in **multiple myeloma**

Discussion

CASPASE FAMILY

The mutations consisted of

- 1) six **missense** mutations,
- 2) four **silent mutations**,
- 3) two mutations in the **introns**,
- 4) one mutation in the **59-untranslated region**,
- 5) and one mutation in the **39-untranslated region**.

Discussion

CASPASE FAMILY

Caspase-9 is a virtually ubiquitous protease, constitutively expressed in a **variety of fetal and adult human tissues**


Mutational analysis

of caspase-9 was performed in **neuroblastoma** tissues

Discussion

CASPASE FAMILY

They isolated **genomic DNAs** from normal and tumour tissues of the same patients




Silent mutations were detected in two **colorectal** carcinomas and one **gastric** carcinoma

Discussion

CASPASE FAMILY

In a **case-control** study,



lung cancer patients and age and gender matched healthy controls were investigated for caspase-9 promoter polymorphism in lung cancer

Discussion

CASPASE FAMILY

They reported that the
-21263 GG genotype
was associated with a
significantly

decreased risk of lung cancer
compared with the -21263 AA
or
the combined 21263 AA + AG
genotype

Discussion

They found that **caspase-9 polymorphisms** were significantly associated with the risk of

CASPASE FAMILY

lung cancer in the **smokers** but not in the **non-smokers**, which reflects a gene–environment interaction

Discussion

CASPASE FAMILY


Such an interaction is biologically plausible because **smoking** is a major risk factor for lung cancer.



It was also found that the association between **caspase-9 polymorphisms** and the risk of lung cancer was statistically significant in the **light smokers but not in the heavy Smokers**(10)

Result

Most of what we know about apoptosis has been developed and understood only recently. The core idea of designing therapeutic drugs for cancer is based on the fact that worn out or damaged cells commit suicide in order for the body to continue to grow normally, maintaining a healthy number of cells, whereas this phenomenon is greatly disturbed in cancer cells.

A microscopic image of cells, possibly cancer cells, showing various cellular structures and nuclei. A large, semi-transparent watermark with the word "SCIENCE" is overlaid on the left side of the image.

Result

we are still left with huge challenges to be overcome.

Development of drugs that act either by blocking the action of antiapoptotic proteins, such as IAPs, small-molecule inhibitors (antisense oligonucleotides),



Result

or by halting, hampering or interference with the transcription of RNA, such as small interfering RNA, BH3 mimetic and some HDACi, holds robust potential for use in cancer therapy; however, the hope to cure cancer is yet to be seen

References

- 1) **Apoptosis** in cancer therapy: crossing the threshold
- 2) **Apoptosis** in cancer therapy: crossing the threshold
- 3) Targeting **apoptosis** pathways in cancer therapy
- 4) The role of **apoptosis** in cancer development and treatment response
- 5) Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling **Smac/Diablo** and **Omi/HtrA2** release from mitochondria
- 6) **Apo2L/TRAIL: apoptosis** signaling, biology, and potential for cancer therapy
- 7) **Oxidative stress** in end-stage renal disease: an emerging threat to patient outcome
- 8) Control of mitochondrial apoptosis by the **Bcl-2** family
- 9) The genetics of the p53 pathway, **apoptosis** and cancer therapy
- 10) ... of **cancer** incidence, **mortality**, and **prevalence** across five continents: defining priorities to reduce **cancer** disparities in different geographic regions of the **world**